Department of Radiology, The Affiliated Renmin Hospital of Jiangsu University, Zhenjiang, Jiangsu 212002, China.
State Key Laboratory of Bioelectronics, Jiangsu Key Laboratory of Biomaterials and Devices, School of Biological Science and Medical Engineering, Southeast University, Nanjing, Jiangsu 210096, China.
Cancer Biomark. 2017;18(4):367-374. doi: 10.3233/CBM-160258.
Breast cancer is one of the most common type of female cancer worldwide and represents 14% of cancer-related deaths in women. Early detection is the most important factor for treatment and prognosis of breast cancer. In most countries, the women are currently screened with mammography only. Even though there has been considerable progress in the detection, surgical therapy, hormonal and target therapy of breast cancer, there are about ∼ 3500 000 women who die from breast cancer each year. Therefore, there is an urgent need to explore the new techniques for early detection of breast cancer. Magnetic resonance imaging (MRI) has the potential to improve breast cancer detection at an early stage because of its higher sensitivity. Glucose transporter (Glut) is a cellular transmembrane receptor that plays key roles in cell glucose metabolism and over-expressed in breast cancer cells. 2-deoxy-D-glucose having a similar structure to D-glucose can specifically interact with Glut.
In the present study, we constructed a 2-deoxy-D-glucose-functionalized superparamagnetic iron oxide (SPIO) nanoparticles that coated with meso-2,3-dimercaptosuccinic acid (γ-Fe2O3@DMSA-DG NPs). The aim of this study is to evaluate the efficacy of new constructed MRI contrast agent (γ-Fe2O3@DMSA-DG NPs) in detecting human breast cancers.
Our results showed that breast cancer cells MDA-MD-231, MCF7 and ZR-75-1 had a high uptake rate of γ-Fe2O3@DMSA-DG NPs than human breast fibroblast cell HUM-CELL-0056. There was a significant difference of T2 relaxation times and signal intensity between breast cancer cells and human breast fibroblast cells labeled with γ-Fe2O3@DMSA-DG NPs when MIR.
Our results indicated that γ-Fe2O3@DMSA-DG NPs may be used as a new MRI contrast agent for detection of breast cancer.
乳腺癌是全球最常见的女性癌症类型之一，占女性癌症相关死亡人数的 14%。早期发现是乳腺癌治疗和预后的最重要因素。在大多数国家，女性目前仅通过乳房 X 光检查进行筛查。尽管在乳腺癌的检测、手术治疗、激素和靶向治疗方面已经取得了相当大的进展，但每年仍有约 350 万女性死于乳腺癌。因此，迫切需要探索乳腺癌早期检测的新技术。磁共振成像（MRI）由于其更高的灵敏度，有可能提高早期乳腺癌的检出率。葡萄糖转运蛋白（Glut）是一种细胞跨膜受体，在细胞葡萄糖代谢中发挥关键作用，在乳腺癌细胞中过度表达。具有与 D-葡萄糖相似结构的 2-脱氧-D-葡萄糖可以与 Glut 特异性相互作用。
在本研究中，我们构建了一种 2-脱氧-D-葡萄糖功能化的超顺磁性氧化铁（SPIO）纳米颗粒，该纳米颗粒涂有间-2,3-二巯基丁二酸（γ-Fe2O3@DMSA-DG NPs）。本研究旨在评估新构建的磁共振成像对比剂（γ-Fe2O3@DMSA-DG NPs）在检测人乳腺癌中的疗效。
我们的结果表明，乳腺癌细胞 MDA-MD-231、MCF7 和 ZR-75-1 对 γ-Fe2O3@DMSA-DG NPs 的摄取率高于人乳腺癌成纤维细胞 HUM-CELL-0056。用 MIR 标记后，乳腺癌细胞和人乳腺癌成纤维细胞之间的 T2 弛豫时间和信号强度有显著差异。
我们的结果表明，γ-Fe2O3@DMSA-DG NPs 可作为一种新的 MRI 对比剂用于乳腺癌的检测。
